Translational Cancer Genomics
Head: Ondřej Slabý
Brno node
HOME INSTITUTION
Faculty of Medicine MU/CEITEC MU
RESEARCH PROGRAMME(S)
RP 3 - Biomarkers of cancers and cancer diagnostics
RP 5 - Translational oncology: Verification clinical studies of the proof-of-concept type
Discovering genetic pathways to recovery!
- Mission: Conduct translational genomics research that advances our knowledge and transforms the lives of cancer patients.
- Vision: Understand how cancer genomes control carcinogenesis and response to cancer therapy, and use this knowledge to benefit patients.
Non-coding RNAs (ncRNAs) have significantly expanded the concept of molecular pathogenesis of cancer and have shown great potential to serve as diagnostic tools and therapeutic targets. In the last two decades, hundreds of individual ncRNAs of different classes have been shown to act as tumor suppressors or oncogenes in a wide range of cancers. However, we still lack a synthesis of this knowledge using systems biology approaches to define ncRNA deregulation as a novel hallmark of cancer.
SELECTED PUBLICATIONS
- Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O. Serum-Based MicroRNA Signatures in Early Diagnosis and Prognosis Prediction of Colon Cancer. Carcinogenesis. 2016;37(10):941-950. DOI: 10.1093/carcin/bgw078
- Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O. MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis. 2017;6(11):399. DOI: 10.1038/s41389-017-0006-6
- Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, De Los Santos MC, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020;159(6):2146-2162.e33. DOI: 10.1053/j.gastro.2020.08.018
- Liu I, Jiang L, Samuelsson ER, Marco Salas S, Beck A, Hack OA, Jeong D, Shaw ML, Englinger B, LaBelle J, Mire HM, Madlener S, Mayr L, Quezada MA, Trissal M, Panditharatna E, Ernst KJ, Vogelzang J, Gatesman TA, Halbert ME, Palova H, Pokorna P, Sterba J, Slaby O, Geyeregger R, Diaz A, Findlay IJ, Dun MD, Resnick A, Suvà ML, Jones DTW, Agnihotri S, Svedlund J, Koschmann C, Haberler C, Czech T, Slavc I, Cotter JA, Ligon KL, Alexandrescu S, Yung WKA, Arrillaga-Romany I, Gojo J, Monje M, Nilsson M, Filbin MG. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet. 2022;54(12):1881-1894. DOI: 10.1038/s41588-022-01236-3
- Palova H, Das A, Pokorna P, Bajciova V, Pavelka Z, Jezova M, Pal K, Dimayacyac JR, Negm L, Stengs L, Bianchi V, Vejmelkova K, Noskova K, Jarosova M, Mejstrikova S, Mudry P, Kyr M, Merta T, Tinka P, Drabova K, Aulicka S, Jugas R, Tabori U, Slaby O, Sterba J. Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome. NPJ Precis Oncol. 2024;8(1):110. DOI: 10.1038/s41698-024-00597-8
COLLABORATION WITHIN THE NICR
Aleksi Šedo
(Prague node, First Faculty of Medicine CU)
David Bednář
(Brno node, Faculty of Science MU)
Jaroslav Štěrba
(Brno node, Faculty of Medicine MU)
Lenka Bešše
(Brno node, Faculty of Medicine MU)
Marián Hajdúch
(Olomouc node, Faculty of Medicine PU in Olomouc)
Pavel Krejčí
(Brno node, Faculty of Medicine MU)
Pavel Vodička
(Prague node, Institute of Experimental Medicine of the Czech Academy of Sciences)
Zdeněk Kleibl
(Prague node, First Faculty of Medicine CU)
SPECIALIZED EXPERTISE AND TECHNOLOGY
Cancer genomics (whole genome, whole exome sequencing, RNA sequencing, small RNA sequencing)
Functional genomics and genome modifications (CRISPR/Cas9)
Processing of challenging biological material for genomic analyses (liquid biopsy, FFPE tissue samples)